A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. [electronic resource]
Producer: 20080624Description: 977-83 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Antibiotics, Antineoplastic -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Squamous Cell -- drug therapy
- Combined Modality Therapy
- Disease-Free Survival
- Docetaxel
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Epothilones -- administration & dosage
- Female
- Head and Neck Neoplasms -- drug therapy
- Hematologic Diseases -- chemically induced
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Paclitaxel -- administration & dosage
- Peripheral Nervous System Diseases -- chemically induced
- Recurrence
- Salvage Therapy
- Survival Analysis
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.